Abstract:Background Hepatopulmonary syndrome (HPS) is characterized by advanced liver disease, hypoxemia and intrapulmonary vascular dilatation (IPVD). The pathogenesis of HPS is not completely understood. Recent findings have established the role of proliferation and phenotype differentiation of pulmonary microvascular endothelial cells (PMVECs) in IPVD of HPS; the change in cytoskeletal proteins and their molecular mechanism play an essential role in the proliferation, phenotype modulation and differentiation of PMVECs. However, little is known about the relevance of cytoskeletal protein expression and its molecular mechanism in IPVD of HPS. In addition, ANX A1 protein has been identified as a key regulator in some important signaling pathways, which influences cytoskeletal remodeling in many diseases, such as lung cancer, liver cancer, etc. Methods PMVECs were cultured from the normal rats and then divided into three groups(Ad-ANXA1-transfected group, a non-transfected group, and an adenovirus empty vector group) and incubated by nomal rat serum or hepatopulmonary syndrome rat serum respectively. mRNA level was evaluated by real time reverse transcription polymerase chain reaction, and protein expression was detected by western blot. Cell proliferation was determined by the MTT and thymidine incorporation assay. Results In this study, we found that the serum from a common bile duct ligation(CBDL) Rat model decreased the expression levels of the ANX A1 mRNA and protein by at least two-fold in human PMVECs. We also found the expression of cytoskeletal proteins (Destrin, a1-actin, and a1-tubulin) in PMVECs significantly increased. After stimulating ANX A1 over-expression in PMVECs by adenovirus-mediated ANX A1 (Ad-ANXA1) transfection, we found the expression levels of cytoskeletal proteins were significantly suppressed in PMVECs at all time points. Additionally, we report here that serum from a CBDL Rat model increases the proliferation of PMVECs by nearly two-fold and that over-expression of Ad-ANXA1 significantly inhibits HPS-rat-serum-induced PMVEC proliferation ( p <0.05). These findings suggest that the ANX A1 down-regulation of PMVEC proliferation in the presence of HPS-rat-serum may be the major cause of aberrant dysregulation of cytoskeletal proteins (Destrin, a1-actin, and a1-tubulin) and may, therefore, play a fundamental role in the proliferation and phenotype differentiation of PMVECs in the PVD of HPS. Conclusion Finally, the fact that transfection with Ad-ANXA1 results in inhibition of the aberrant dysregulation of cytoskeletal proteins and proliferation of PMVECs suggests a potential therapeutic effect on PVD of HPS.

MiR-206 controls the phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum from rats with hepatopulmonary syndrome by regulating the target gene, annexin A2.

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

The Regulatory Effect of Microrna-21A-3p on the Promotion of Telocyte Angiogenesis Mediated by PI3K (p110α)/akt/mtor in LPS Induced Mice ARDS

Effect of Annexin A2 on Hepatopulmonary Syndrome Rat Serum-Induced Proliferation of Pulmonary Arterial Smooth Muscle Cells

Annexin A2 Inhibits the Migration of PASMCs Stimulated with HPS Rat Serum by Down-Regulating the Expression of Paxillin

MicroRNA-221-3p Promotes Pulmonary Artery Smooth Muscle Cells Proliferation by Targeting AXIN2 During Pulmonary Arterial Hypertension.

Requirement of miR‐9‐dependent regulation of Myocd in PASMCs phenotypic modulation and proliferation induced by hepatopulmonary syndrome rat serum

Mir144-3P Inhibits PMVECs Excessive Proliferation in Angiogenesis of Hepatopulmonary Syndrome Via Tie2

MiR145-5p Inhibits Proliferation of PMVECs Via PAI-1 in Experimental Hepatopulmonary Syndrome Rat Pulmonary Microvascular Hyperplasia.

Human pulmonary artery smooth muscle cell dysfunction is regulated by miR-509-5p in hypoxic environment

MicroRNA-222 Promotes the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Targeting P27 and TIMP3

miR-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension

MicroRNA-221 Promotes Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells (pasmcs) by Targeting Tissue Inhibitor of Metalloproteinases-3 (TIMP3).

MicroRNA-101 inhibits proliferation of pulmonary microvascular endothelial cells in a rat model of hepatopulmonary syndrome by targeting the JAK2/STAT3 signaling pathway.

miR-17/20 Controls Prolyl Hydroxylase 2 (PHD2)/Hypoxia-Inducible Factor 1 (HIF1) to Regulate Pulmonary Artery Smooth Muscle Cell Proliferation

MicroRNA-663 Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension by Targeting TGF-β1/smad2/3 Signaling

MiR-122-5p As a Potential Regulator of Pulmonary Vascular Wall Cell in Idiopathic Pulmonary Arterial Hypertension

Reverse the down regulation of miR-92b-3p by hypoxia can suppress the proliferation of pulmonary artery smooth muscle cells by targeting USP28

Annexin A2-modulated proliferation of pulmonary arterial smooth muscle cells depends on caveolae and caveolin-1 in hepatopulmonary syndrome

MicroRNA-223 Attenuates Hypoxia-induced Vascular Remodeling by Targeting RhoB/MLC2 in Pulmonary Arterial Smooth Muscle Cells

Annexin A1 Protein Regulates the Expression of PMVEC Cytoskeletal Proteins in CBDL Rat Serum-Induced Pulmonary Microvascular Remodeling